896 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Gradient Investments LLC

Gradient Investments LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, Holdings Channel.com reports. The firm purchased 896 shares of the biopharmaceutical company’s stock, valued at approximately $692,000.

A number of other hedge funds have also recently bought and sold shares of REGN. Salomon & Ludwin LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at $31,000. Board of the Pension Protection Fund bought a new position in Regeneron Pharmaceuticals during the 4th quarter valued at $31,000. Caitlin John LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at $34,000. Finally, Berbice Capital Management LLC boosted its stake in Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 60 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.7%

Shares of NASDAQ:REGN opened at $741.69 on Wednesday. The company’s fifty day moving average is $764.37 and its two-hundred day moving average is $704.03. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The stock has a market capitalization of $78.41 billion, a price-to-earnings ratio of 17.85, a price-to-earnings-growth ratio of 1.98 and a beta of 0.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the business posted $12.07 EPS. The company’s quarterly revenue was up 2.5% on a year-over-year basis. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a $0.94 dividend. The ex-dividend date was Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.05%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on REGN. Evercore boosted their target price on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Cantor Fitzgerald increased their price target on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Finally, Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and upped their price objective for the company from $627.00 to $860.00 in a research note on Wednesday, January 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $802.27.

Insider Buying and Selling

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the transaction, the director directly owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 5,274 shares of company stock valued at $4,142,738 over the last three months. 7.02% of the stock is owned by company insiders.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Sanofi & Regeneron’s Dupixent (dupilumab) was approved in Japan as the first targeted treatment for adults with bullous pemphigoid (BP). Approval was based on pivotal data showing over four times more Dupixent patients achieved sustained remission through Week 36 vs placebo; this is Dupixent’s seventh approved indication in Japan and expands its commercial footprint and near‑term revenue potential in a new specialty indication. Dupixent Japan Approval (GlobeNewswire)
• Neutral Sentiment: Multiple short‑interest reports show a reported increase in March but list short interest as 0 shares and “NaN” changes — producing a days‑to‑cover of 0.0. This appears to be a data/reporting anomaly and is unlikely to be a meaningful driver for the stock until clearer short‑interest figures are published.
• Negative Sentiment: Apogee Therapeutics reported Phase 2 data for a long‑acting eczema therapy (zumilokibart) that supports dosing every 3–6 months; Apogee shares jumped ~20% on the news. If that program advances, it represents a potential long‑term competitive threat to Dupixent in atopic dermatitis and could pressure future market share or pricing in certain segments. Apogee Phase 2 results (BioPharmaDive)

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.